


Study Results IMmotion 151

A study of atezolizumab in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma


source : [www.urotoday.com/conference-highlights/asco-gu-2018:IMmotion 151](http://www.urotoday.com/conference-highlights/asco-gu-2018:IMmotion151)



915
Patients




165
Trial Sites





21
Countries

Trial Design


Lorem ipsum




Objective Response Rate (ORR)



Progression Free Survival (PFS)



Complete Response (CR)




Overall Survival (OS)



Side Effects

Grade 3 or Grade 4



© IKCC = International Kidney Cancer Coalition, www.ikcc.org, www.10forio.info

* Overall Survival Data Has Not Yet Matured
Last Revised: December 14, 2018

